First Time Loading...

JW (Cayman) Therapeutics Co Ltd
HKEX:2126

Watchlist Manager
JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Watchlist
Price: 1.83 HKD -0.54%
Updated: May 9, 2024
JW (Cayman) Therapeutics Co Ltd
/
Income Statement
/
Income from Continuing Operations

JW (Cayman) Therapeutics Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

JW (Cayman) Therapeutics Co Ltd
Income from Continuing Operations Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Income from Continuing Operations
-¥768m
CAGR 3-Years
23%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Income from Continuing Operations
-¥13.6B
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Income from Continuing Operations
-¥1B
CAGR 3-Years
-1%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Income from Continuing Operations
¥1.2B
CAGR 3-Years
22%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Income from Continuing Operations
¥8.5B
CAGR 3-Years
40%
CAGR 5-Years
47%
CAGR 10-Years
45%
Imeik Technology Development Co Ltd
SZSE:300896
Income from Continuing Operations
¥1.3B
CAGR 3-Years
62%
CAGR 5-Years
75%
CAGR 10-Years
N/A

See Also

What is JW (Cayman) Therapeutics Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
-768m CNY

Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Income from Continuing Operations amounts to -768m CNY.

What is JW (Cayman) Therapeutics Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-23%

Over the last year, the Income from Continuing Operations growth was 9%. The average annual Income from Continuing Operations growth rates for JW (Cayman) Therapeutics Co Ltd have been 23% over the past three years , -23% over the past five years .

ALPHA SPREAD
Join more than 135,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.